Tweet
Hi everyone. I prepped some samples with Nextera xt kit and run them on the next seq. I monitored the run and everything was fine until the uploading step. I can see cluster density, %pf and %q30, and in the run completion file it says CompletedAsPlanned. So I don't understand why in the status it says Failed. Can you guys help me troubleshooting? Seems like nothing has gone wrong.
-
-
Sounds like you do your analysis in BaseSpace? Was there a network failure of some kind?
Your best bet is to engage Illumina techsupport but someone else who uses BaseSpace may be able to help. -
I use basespace to monitor the run status remotely and also to download the fastq file because the nextseq machine is shared with other people so we use it just to set up the sequencing. I just don't understand why it stopped. I can actually see a fastq file generated but the size is small probably because it has data just for a few samples?Comment
-
This has happened to me with the MiSeq and it was a problem with the sample sheet that kept the run from demuxing. If this is what happened then the error log will tell you which lines of your sheet need to be fixed.Josh KinmanComment
-
Thank you jdk787. I have double checked the sample sheet and this is fine. I can't see any error log file, could you please remind me where to look for it please?Comment
-
Issue solved. There was a network failure so I requeued the analysis and now it's fine!!Comment
-
Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.
The systematic characterization of the human proteome has...07-20-2026, 11:48 AM -
Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
...07-09-2026, 11:10 AM -
Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.
There is no single reason why many patients don’t respond to treatment as expected. Cancer is...07-08-2026, 05:17 AM
Comment